Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection

Ingrid Karlsson, Lea Brandt, Lasse Vinner, Ingrid Kromann, Lars Vibe Andreasen, Peter Andersen, Jan Gerstoft, Gitte Kronborg, Anders Fomsgaard

37 Citationer (Scopus)

Abstract

We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals.
OriginalsprogEngelsk
TidsskriftClinical immunology (Orlando, Fla.)
Vol/bind146
Udgave nummer2
Sider (fra-til)120-30
Antal sider11
ISSN1521-6616
DOI
StatusUdgivet - feb. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection'. Sammen danner de et unikt fingeraftryk.

Citationsformater